Loading…
Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.
Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.
Hemgenix, the hemophilia B gene therapy, is sold by CSL Behring, so uniQure's own income from it comes as milestone and royalty payments rather than product sales. With nothing else on the market, it finances its main programme, a one-time gene therapy delivered into the brain for Huntington's disease, with those payments and share sales.
Moat: narrow (IP / patents, process know-how). Pioneer in AAV gene therapy manufacturing with an approved product and a royalty stream from CSL Behring.
Headquarters: Amsterdam, Netherlands · Founded: 1998 · Employees: 221
Size uniQure (QURE) is a United States Health Care company (Biotechnology) with a market value of $1.51B, the 1988th largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.70 on 6 Nov 2026.
Performance Over six months the shares fell 21.6%, against -18.7% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue grew 30.2% over the last twelve months (peer median +22.1%); the operating margin is -1,093.2% (peer median -46.1%).
Valuation It trades at 66.8× enterprise value to sales against a peer median of 14.8× (7th most expensive of 17).
Short interest Short interest is 12.6% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $18.7M | $16.1M | $27.1M | $15.8M | $106M |
| Revenue growth | — | -41% | +71% | -85% | — |
| Gross profit | $2.81M | -$347,000 | -$3.85M | -$9.69M | $94.6M |
| EBITDA | -$190M | -$171M | -$172M | -$259M | -$134M |
| Net income | -$252M | -$199M | -$240M | -$308M | -$127M |
| Free cash flow | -$164M | -$178M | -$186M | -$153M | -$163M |
| Capital expenditure | $662,182 | $439,000 | $11.7M | $7.15M | $17.7M |
| Total debt | $552M | $537M | $501M | $533M | $143M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| uniQure QURE | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a |
| Sarepta Therapeutics SRPT | $1.88B | -11% | -20% | -3% | 1.1× | 11.9% |
| BioMarin Pharmaceutical BMRN | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% |
| PTC Therapeutics PTCT | $5.47B | -11% | -35% | 22% | 3.4× | 8.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | QURE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.7% | -4.3% | 11th highest of 21 |
| 6-month return | -21.6% | -18.7% | 7th lowest of 18 |
| Distance from 52-week high | -58.0% | -40.7% | 2nd lowest of 21 |
| Revenue growth (TTM) | +30.2% | +22.1% | 8th highest of 18 |
| Operating margin | -1,093.2% | -46.1% | 4th lowest of 18 |
| EV / Sales | 66.8× | 14.8× | 7th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |